Study to determine the safety tolerability pharmacokinetics and pharmacodynamics of DNL201 in subjects with Parkinsons Disease

  • STATUS
    Enrolling By Invitation
  • participants needed
    6
Send
Updated on 19 February 2024

Summary

The purpose of this research is to investigate whether DNL201 (the study drug) is safe and tolerable in Parkinson’s disease patients and to investigate how DNL201 is absorbed, broken down, and eliminated from the body. ™ 


Description

Duration: It is expected that your participation will last approximately 10 weeks, including the Follow-Up Period. The Treatment Period for this study is approximately 28 days. ™
Procedures and Activities: During this study, you will be required to visit the study site at least 8 times, not including the Screening Period. Two of these visits include inpatient stays (overnight) for 5 days and 4 nights. For the first inpatient stay, you will be admitted to the Center for Human Phenomic Science (CHPS) starting 2 days prior to the date of the first dose of study drug (the Baseline Period) through Day 3 of the Treatment Period. The second inpatient stay will start near the end of the Treatment Period during which you will be admitted to the inpatient unit starting on Day 26 through Day 30.

FAQ


Details
Condition PARKINSONS DISEASE
Age 18years - 99years
Clinical Study Identifier03710707
Last Modified on19 February 2024

Eligibility

If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.